Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNACTHIV: Safety and Tolerability of Decitabine and Romidepsin in HIV+ Patients
NCT05230368Phase 1Completed
- Sponsor
- ANRS
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of decitabine and romidepsin in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by ANRS. Primary endpoint: Incidence of Serious Adverse Events (SAE) and severe clinical or biological adverse events (AE) related to the study drugs. Started Dec 2022; status: completed.
02
Drugs
decitabineromidepsin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05230368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230368.